Evaluación del potencial terapéutico del trasplante de microbiota fecal en la enfermedad hepática esteatósica: conocimientos actuales y vías futuras

Abstract

The pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Dis-ease (MASLD) is multifaceted, involving an intricate interaction among genetic predis-position, diet, environmental factors, lifestyle choices, and the gut micro-biome (GM). The complexity of these interactions may explain the difficulties to obtain an effective pharmacological treatment for MASLD. Purpose of review: To explain the relevance of Fecal Microbiota Transplantation (FMT) for the treatment of MASLD, the scientific evi-dence supporting its usefulness, and the difficulties of its translation into effective treatments for use in routine clinical practice. Recent findings: FMT has been proven effective and safety in other indications and several procedures have been testing for delivery of fecal microbiota to the intestine. The field awaits results from ongoing clinical trials to better understand the role of FMT in the management of MASLD.